Codexis, Inc. (CDXS) is a Materials stock trading at $1.66 (as of 2026-08-21), with a market capitalization of $181.78M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Codexis discovers, develops, and sells enzymes and other proteins, including biocatalyst products and services, intermediate chemicals used in further processing, biocatalyst panels and kits, and protein engineering offerings such as the CodeEvolver platform, earning money from product revenue and related service and platform activity.
Because gross profit is high but operating margin is deeply negative, the profit model depends on whether enzyme and platform-related revenue can grow enough to cover ongoing operating costs tied to development and commercial scaling, especially versus biotherapeutics progress.
| Perf Enzymes | $0.0B |
| Biotherapeutics | $0.0B |
Business quality (Weak): High disclosed gross margin, but the latest period shows deeply negative operating margin, with segment revenue appearing very small in this snapshot, so near-term results look heavily driven by the cost structure and product mix rather than scale.
| Price | $1.66 |
| Market Cap | $181.78M |
| Price / Book | 5.52 |
| Price / Sales | 2.34 |
| FCF Yield | -28.7% |
| Revenue (TTM) | $70.39M |
| Net Margin | -62.5% |
| Revenue Growth (YoY) | -2.7% |
| EPS Growth (YoY) | -18.8% |
| FCF Growth (YoY) | -48.5% |
| Altman Z-Score | -4.69 (distress) |
| Piotroski F-Score | 4/9 (moderate) |
| Sector P/E (Materials) | 25.9 |
| Industry P/E (Chemicals) | 31.1 |
| Top Institutional Holder | Aberdeen Group plc ($14.15M) |
| Institutional Holders Tracked | 10 |
| Sector | Materials |
| Industry | Chemicals |
| CEO | Alison Moore |
| Employees | 188 |
| Country | US |
| IPO Date | 2010-04-22 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.